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ABSTRACT: Current sustained delivery strategies of
protein therapeutics are limited by the fragility of the
protein, resulting in minimal quantities of bioactive protein
delivered. In order to achieve prolonged release of
bioactive protein, an affinity-based approach was designed
which exploits the specific binding of the Src homology 3
(SH3) domain with short proline-rich peptides. Specifi-
cally, methyl cellulose was modified with SH3-binding
peptides (MC-peptide) with either a weak affinity or
strong affinity for SH3. The release profile of SH3-rhFGF2
fusion protein from hyaluronan MC-SH3 peptide
(HAMC-peptide) hydrogels was investigated and com-
pared to unmodified controls. SH3-rhFGF2 release from
HAMC-peptide was extended to 10 days using peptides
with different binding affinities compared to the 48 h
release from unmodified HAMC. This system is capable of
delivering additional proteins with tunable rates of release,
while maintaining bioactivity, and thus is broadly
applicable.
M
any promising therapeutics are increasingly protein-
based;
1−3 however, bioactive protein delivery remains a
challenge.
4 Two main approaches have emerged to control
protein release: (i) encapsulation in nano/microparticles, which
provides a diffusive barrier and (ii) incorporation in affinity-
based drug delivery systems, which establishes a dynamic
equilibrium to delay release.
5,6 Although protein encapsulation
is common, the harsh environments (organic solvents,
aqueous/organic interfacial free energy, shear force, and
lyophilization) present during the encapsulation process can
diminish protein bioactivity and drug loading is generally low.
7,8
Affinity-based release systems overcome these limitations by
sequestering proteins, commonly growth factors, in a matrix,
much like the extracellular matrix in vivo. These systems
generally consist of a hydrogel that has been chemically
modified to bind a growth factor with moderate or high affinity,
depending on the required rate of release, to attenuate the
diffusional release of the protein.
6 For example, heparin or
heparin-binding peptides have been immobilized to various
matrices to deliver a variety of heparin-binding proteins;
9−18
however, this approach is inherently limited to heparin-binding
proteins. Recombinant human basic fibroblast growth factor
(rhFGF2) binding peptide can be used to control the release of
rhFGF2 from PEG hydrogels and, yet, is similarly limited to
FGF2.
19 Collagen scaffolds have been shown to bind
therapeutic fusion proteins that contain a collagen binding
domain;
20 however, this system requires collagen as a scaffold
and the rate of release cannot be tuned. A system which can
deliver a diversity of proteins with a tunable rate of protein
release is required.
We have developed a versatile hydrogel that combines both
of these properties to deliver therapeutic proteins at tunable
rates of release. Importantly, our system is amenable to a variety
of proteins.
An injectable, fast gelling blend of two polysaccharides,
hyaluronan (HA) and methyl cellulose (MC), provides
minimally invasive, localized drug delivery to the injured spinal
cord and brain.
21,22 Additionally, HAMC can be loaded with
proteins to provide localized, diffusion-mediated release.
Protein release from HAMC is complete within 1 to 2 days
in vitro;
23,24 however, factors must often be available for longer
times to elicit functional recovery.
25,26 Thus, extending the
protein release profile of this therapeutic drug delivery matrix
would improve administration of an exciting new class of drugs.
Here we present a platform technology that permits
minimally invasive and localized delivery of therapeutic proteins
with tunable and extended release profiles. We used HAMC as
a drug delivery matrix and exploited peptide−protein
interactions to develop a system adaptable to any protein
with the ability to finely tune the rate of its release from the
matrix. We are interested in the delivery of rhFGF2 in these
studies because it is a neuroprotective, angiogenic factor that
requires at least 5 days of continuous delivery to achieve tissue
and functional benefit in rat models of spinal cord injury.
27
To achieve sustained release of this protein from the HAMC
hydrogel, rhFGF2 was expressed in Escherichia coli (E. coli)a sa
fusion protein with the Src homology 3 domain (SH3) (SH3-
rhFGF2, Figure 1) and MC was modified with one of two SH3-
binding peptides (Scheme 1). Specifically, chemical modifica-
tion of methyl cellulose, MC (1), was achieved starting with a
Williamson ether synthesis
28 to produce carboxylated MC 2.
This was then coupled with 3,3′-dithiobis(propionic dihydra-
zide)
29 using 1-ethyl-3-[3-(dimethylamino)propyl]-
carbodiimide (EDC), followed by disulfide reduction with
dithiothreitol (DTT) to yield thiolated MC 3 (Scheme 1,
Figure S1, Supporting Information (SI)). Thiolated MC was
reacted with 3-maleimidopropionic-SH3-binding peptide (4,5)
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(MC-peptide) 6 or 7. The latter was then combined with
unmodified HA to form HAMC-peptide. HA decreases the
gelation temperature of MC, resulting in a fast gelling polymer
that is also easily injectable through a fine needle due to the
shear-thinning property of HA.
21
SH3 has previously been shown to bind to various proline-
rich peptide sequences with different affinities (Kd) ranging
from 10−5 to 10−7 M.
30 Two different SH3-binding peptides
with varying affinity to SH3 (4, Kd = 2.7 × 10−5 Mo r5, Kd =
2.7 × 10−7 M) were tested in our system as a way to control
release. As shown in Figure 1, we hypothesized that transient
interactions between the binding pairs would slow the diffusion
of SH3-rhFGF2 from the matrix. Thus, the rate of release could
be tuned by either changing the concentration of the binding
peptide or using binding peptides with different affinities, where
peptides with stronger affinities would further attenuate release.
MC was modified with one of two peptides that have
different binding affinities to SH3: KPPVVKKPHYLS (weak
binder, 4, Kd = 2.7 × 10−5 M) and KKTKPTPPPKPSHLKPK
(strong binder, 5, Kd = 2.7 × 10−7 M).
30 Three glycine residues
were incorporated at the N-terminus of the SH3-binding
peptide to facilitate protein−peptide recognition and binding
once the peptide was covalently attached to the MC hydrogel.
This spacer minimizes possible steric hindrance that may affect
binding interactions of immobilized ligands with the corre-
sponding protein.
19 A substitution rate of 1 SH3-binding
peptide per 15 monomer units, or 180−200 μmol peptide/g
MC (Figure S2, SI), was consistently achieved for each peptide.
MC-peptide (3 wt %) was then simply blended with HA (1 wt
%) to form a physical hydrogel blend of HAMC-peptide.
A bifunctional fusion protein of SH3 and rhFGF2 was
designed to include a small linker region between SH3 and
rhFGF2 that acts as a hinge to ensure each protein will fold
correctly and function as it does in its native state.
31 While the
SH3 domain can be bound at either the N- or C-terminus of
the fusion protein, it was bound at the N-terminus of rhFGF2
to maintain bioactivity. The fusion protein was expressed in
BL21 E. coli and purified via a hexahistidine tag using a nickel
affinity column. The fusion protein was characterized by mass
spectrometry (Figure S3, SI) and denaturing gel electrophoresis
(Figure S4, SI). To confirm the rhFGF2 portion of the fusion
protein was still bioactive, a cell survival assay using mouse-
derived neural stem progenitor cells was performed.
32 The
activity of the fusion protein was identical to that of commercial
rhFGF2 (p > 0.05), indicating that bioactivity was preserved in
the fusion protein (Figure S5, SI).
Release of SH3-rhFGF2 (20 μM) was investigated in vitro
under conditions that mimic the in vivo environment of the
spinal cord. Artificial cerebrospinal fluid with 0.2 mg/mL
heparin was used as a release buffer and was added to tubes
containing HAMC and HAMC-peptide (188 μmol peptide/g
MC) hydrogels. Tubes were placed on an oscillatory shaker at
37 °C, and release buffer was completely removed and replaced
with fresh buffer at multiple time points. Release samples were
frozen at −20 °C until protein was assayed by an enzyme-
linked immunosorbent assay (ELISA). Data are presented as
cumulative protein release (relative to initial protein loaded) as
a function of time. Data normalized to the total amount of
protein detected are shown in Figure S6, SI. Release of SH3-
rhFGF2 from HAMC alone was nearly complete at 2 days
whereas release from HAMC-peptide hydrogels (HAMC-weak
binder and HAMC-strong binder) extended to more than 10
days (Figure 2A).
The fastest release was obtained from HAMC, followed by
HAMC-weak binder and HAMC-strong binder, and was
statistically significant between all groups (p < 0.001) except
between HAMC-weak binder and HAMC-strong binder at t =
1 and 2 h (p < 0.05). This confirms the hypothesis that tunable
release profiles are achieved by changing the affinity of the
binding peptide.
To investigate differences in the diffusion coefficient of SH3-
rhFGF2 in the three hydrogels, we plotted fractional protein
release against the square root of time (t1/2, Figure 2B). In this
plot, a linear relationship is indicative of Fickian diffusion.
33 By
comparing the slopes in the linear region for each hydrogel, we
determined that the relative diffusion coefficient for SH3-
rhFGF2 was significantly different for each gel (p < 0.001). For
HAMC alone, the data fit linearly for the first 8 h of release,
similar to published data for diffusional release of immunoglo-
bulin G and α-chymotrypsin from HAMC.
23 Notably, for
HAMC-weak binder and HAMC-strong binder the data fit
linearly for 5 and 10 days of release respectively. This confirms
that release from HAMC-peptide hydrogels, which is sustained
Figure 1. Controlled release of SH3-rhFGF2 from hydrogels modified
with SH3-binding peptides. Transient association between SH3-
binding peptides covalently bound to methyl cellulose and the SH3
protein modulate release of the fusion protein SH3-rhFGF2 from the
matrix.
Scheme 1. Synthesis of Methyl Cellulose-Peptide
a
aReagents: (a) 3 M bromoacetic acid, 1 M NaOH, 3 h, 4 °C. (b) (i)
EDC, 3,3′-dithiobis(propionic dihydrazide), pH 4.5, 2 h, rt. (ii) DTT,
pH 8.5, 24 h, rt. (c) 4 or 5, PBS, pH 6.8, N2(g), 24 h, rt.
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Importantly, protein release from HAMC-peptide hydrogels is
linear, overcoming the burst and biphasic release often
observed in encapsulated drug delivery systems.
34 Since these
HAMC hydrogels have been shown to be stable in vitro for over
28 days,
23 neither polymer degradation nor dissolution was
expected to affect the release profile. Thus, immobilizing SH3-
binding peptides to HAMC confers the ability to tune the rate
of diffusion-controlled release of SH3 fusion proteins.
The release profile for a drug can have a dramatic effect on
the effectiveness of the therapy. Consequently, a priority of
drug delivery system design is to allow tunable release rates.
Herein, we showed that the release of a therapeutic fusion
protein can be controlled through physical binding interactions
with a biomaterial matrix. Protein release is linear and tunable.
This versatile and simple system demonstrates several improve-
ments over current affinity-based release systems, the most
important of which is its broad applicability to a variety of
proteins and a diversity of materials. Several protein-peptide
binding pairs can be investigated to achieve tunable release of
multiple proteins and at distinct rates of release.
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